CytomX Therapeutics, Inc.
CTMX
CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops antibody therapeutics based on its Probody technology platform for the treatment of cancer. The company's product candidates include CX-2009, an antibody drug conjugates (ADC) against CD166, which is in Phase II clinical trials for the treatment of breast cancer; CX-2029 tā¦ read more
Healthcare
Biotechnology
10 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$3.62
Price-13.60%
-$0.57
1Y
Price
Market Cap
$596.985m
Small
Price/Earnings 3y Avg5y Avg
7.2x
Premium
Premium
Financials Overview
Key metrics over the past few years-5.0%
EBITDA Margin-0.8%
Net Profit Margin-84.6%
Free Cash Flow MarginRevenue
$141.100m
+2.2%
1y CAGR+43.0%
3y CAGR+26.4%
5y CAGREarnings
$47.983m
+50.6%
1y CAGR+1950.3%
3y CAGR+1457.6%
5y CAGREPS
$0.58
+52.6%
1y CAGR+1350.7%
3y CAGR+1008.6%
5y CAGRBook Value
$119.910m
$175.057m
Assets$55.147m
Liabilities$6.885m
DebtDebt to Assets
3.9%
0.1x
Debt to EBITDAFree Cash Flow
-$77.678m
+10.2%
1y CAGR+2.5%
3y CAGR+3.6%
5y CAGRFinancial Reports
Earnings and other important metrics. Amounts in USD.No items found.
Press Releases
Statements and updates from the company